Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen

M. S. Soloway, T. Hachiya, H. E. Ruiz, C. C. Gomez, Francisco Civantos

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

A total of 37 selected patients with clinical stage T2b or T3 prostate cancer received androgen deprivation prior to radical retropubic prostatectomy. A luteinizing hormone-releasing hormone (LHRH) analog alone was given to 15 individuals; 19 received an LHRH analog with flutamide. Three underwent bilateral orchiectomy instead of chemical castration. The duration of androgen deprivation prior to radical prostatectomy varied from 3 to 16 months, with 31 individuals undergoing induction therapy for 3-6 months. Three received androgen deprivation for more than 1 year. In all, 15 patients had clinical stage T2b disease and 22, stage T3 prostate cancer. The prostate size decreased approximately 30%-50% following induction therapy. Prostate-specific antigen (PSA) values decreased in all 19 instances where this was obtained. In all, 6 of 15 (40%) patients with clinical T2b lesions and 9 of 22 (41%) with clinical T3 tumors had a positive surgical margin; 5 (13%) had 1 or more positive lymph nodes. Androgen deprivation was continued following surgery in 13 cases. Only one patient received postoperative radiation therapy. After a mean follow-up period of 33 months, 35 (95%) patients are alive. Two patients died, one of poorly differentiated prostate cancer with subsequent metastasis and one of a myocardial infarction 33 months after surgery without showing any evidence of disease. Of 23 patients without postoperative adjuvant therapy, 6 (26,1%) progressed (PSA level, >0.4 ng/ml). None of the patients who underwent adjuvant therapy progressed over a follow-up period of 6-75 months (mean, 38 months). Although the low incidence of positive lymph nodes and the apparent reduction in tumor size after androgen deprivation are encouraging, the benefits of this approach must await the completion of ongoing randomized trials.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalWorld Journal of Urology
Volume11
Issue number4
DOIs
StatePublished - Dec 1 1993

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Androgens
Prostatic Neoplasms
Gonadotropin-Releasing Hormone
Lymph Nodes
Flutamide
Orchiectomy
Castration
Therapeutics
Prostate
Neoplasms
Radiotherapy
Myocardial Infarction
Neoplasm Metastasis
Incidence

ASJC Scopus subject areas

  • Urology

Cite this

Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen. / Soloway, M. S.; Hachiya, T.; Ruiz, H. E.; Gomez, C. C.; Civantos, Francisco.

In: World Journal of Urology, Vol. 11, No. 4, 01.12.1993, p. 221-226.

Research output: Contribution to journalArticle

@article{cccec1c460034c65adf125464429305f,
title = "Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen",
abstract = "A total of 37 selected patients with clinical stage T2b or T3 prostate cancer received androgen deprivation prior to radical retropubic prostatectomy. A luteinizing hormone-releasing hormone (LHRH) analog alone was given to 15 individuals; 19 received an LHRH analog with flutamide. Three underwent bilateral orchiectomy instead of chemical castration. The duration of androgen deprivation prior to radical prostatectomy varied from 3 to 16 months, with 31 individuals undergoing induction therapy for 3-6 months. Three received androgen deprivation for more than 1 year. In all, 15 patients had clinical stage T2b disease and 22, stage T3 prostate cancer. The prostate size decreased approximately 30{\%}-50{\%} following induction therapy. Prostate-specific antigen (PSA) values decreased in all 19 instances where this was obtained. In all, 6 of 15 (40{\%}) patients with clinical T2b lesions and 9 of 22 (41{\%}) with clinical T3 tumors had a positive surgical margin; 5 (13{\%}) had 1 or more positive lymph nodes. Androgen deprivation was continued following surgery in 13 cases. Only one patient received postoperative radiation therapy. After a mean follow-up period of 33 months, 35 (95{\%}) patients are alive. Two patients died, one of poorly differentiated prostate cancer with subsequent metastasis and one of a myocardial infarction 33 months after surgery without showing any evidence of disease. Of 23 patients without postoperative adjuvant therapy, 6 (26,1{\%}) progressed (PSA level, >0.4 ng/ml). None of the patients who underwent adjuvant therapy progressed over a follow-up period of 6-75 months (mean, 38 months). Although the low incidence of positive lymph nodes and the apparent reduction in tumor size after androgen deprivation are encouraging, the benefits of this approach must await the completion of ongoing randomized trials.",
author = "Soloway, {M. S.} and T. Hachiya and Ruiz, {H. E.} and Gomez, {C. C.} and Francisco Civantos",
year = "1993",
month = "12",
day = "1",
doi = "10.1007/BF00185074",
language = "English",
volume = "11",
pages = "221--226",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen

AU - Soloway, M. S.

AU - Hachiya, T.

AU - Ruiz, H. E.

AU - Gomez, C. C.

AU - Civantos, Francisco

PY - 1993/12/1

Y1 - 1993/12/1

N2 - A total of 37 selected patients with clinical stage T2b or T3 prostate cancer received androgen deprivation prior to radical retropubic prostatectomy. A luteinizing hormone-releasing hormone (LHRH) analog alone was given to 15 individuals; 19 received an LHRH analog with flutamide. Three underwent bilateral orchiectomy instead of chemical castration. The duration of androgen deprivation prior to radical prostatectomy varied from 3 to 16 months, with 31 individuals undergoing induction therapy for 3-6 months. Three received androgen deprivation for more than 1 year. In all, 15 patients had clinical stage T2b disease and 22, stage T3 prostate cancer. The prostate size decreased approximately 30%-50% following induction therapy. Prostate-specific antigen (PSA) values decreased in all 19 instances where this was obtained. In all, 6 of 15 (40%) patients with clinical T2b lesions and 9 of 22 (41%) with clinical T3 tumors had a positive surgical margin; 5 (13%) had 1 or more positive lymph nodes. Androgen deprivation was continued following surgery in 13 cases. Only one patient received postoperative radiation therapy. After a mean follow-up period of 33 months, 35 (95%) patients are alive. Two patients died, one of poorly differentiated prostate cancer with subsequent metastasis and one of a myocardial infarction 33 months after surgery without showing any evidence of disease. Of 23 patients without postoperative adjuvant therapy, 6 (26,1%) progressed (PSA level, >0.4 ng/ml). None of the patients who underwent adjuvant therapy progressed over a follow-up period of 6-75 months (mean, 38 months). Although the low incidence of positive lymph nodes and the apparent reduction in tumor size after androgen deprivation are encouraging, the benefits of this approach must await the completion of ongoing randomized trials.

AB - A total of 37 selected patients with clinical stage T2b or T3 prostate cancer received androgen deprivation prior to radical retropubic prostatectomy. A luteinizing hormone-releasing hormone (LHRH) analog alone was given to 15 individuals; 19 received an LHRH analog with flutamide. Three underwent bilateral orchiectomy instead of chemical castration. The duration of androgen deprivation prior to radical prostatectomy varied from 3 to 16 months, with 31 individuals undergoing induction therapy for 3-6 months. Three received androgen deprivation for more than 1 year. In all, 15 patients had clinical stage T2b disease and 22, stage T3 prostate cancer. The prostate size decreased approximately 30%-50% following induction therapy. Prostate-specific antigen (PSA) values decreased in all 19 instances where this was obtained. In all, 6 of 15 (40%) patients with clinical T2b lesions and 9 of 22 (41%) with clinical T3 tumors had a positive surgical margin; 5 (13%) had 1 or more positive lymph nodes. Androgen deprivation was continued following surgery in 13 cases. Only one patient received postoperative radiation therapy. After a mean follow-up period of 33 months, 35 (95%) patients are alive. Two patients died, one of poorly differentiated prostate cancer with subsequent metastasis and one of a myocardial infarction 33 months after surgery without showing any evidence of disease. Of 23 patients without postoperative adjuvant therapy, 6 (26,1%) progressed (PSA level, >0.4 ng/ml). None of the patients who underwent adjuvant therapy progressed over a follow-up period of 6-75 months (mean, 38 months). Although the low incidence of positive lymph nodes and the apparent reduction in tumor size after androgen deprivation are encouraging, the benefits of this approach must await the completion of ongoing randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=0027736230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027736230&partnerID=8YFLogxK

U2 - 10.1007/BF00185074

DO - 10.1007/BF00185074

M3 - Article

C2 - 7508788

AN - SCOPUS:0027736230

VL - 11

SP - 221

EP - 226

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 4

ER -